Effect of roxatidine acetate on daytime and night-time peptone-stimulated gastric acid secretion.
A double-blind, randomised, crossover study in 12 healthy volunteers was performed to assess the effects of roxatidine acetate 75 mg or placebo administered at 8 am and 9 pm on peptone-stimulated hydrochloric acid secretion. In comparison to placebo, roxatidine acetate produced an average reduction of daytime hydrochloric acid output of 86% and 32%, respectively, for the 4- to 6-hour and 10- to 12-hour post-drug administration phases. In addition, roxatidine acetate produced reductions in nocturnal hydrochloric acid output of 75 to 92% with an associated rise in intragastric pH of around 2 units compared to placebo. No side effects or clinically significant alterations in haematological or biochemical values were reported following roxatidine acetate administration. These results suggest that roxatidine acetate is a potent and effective inhibitor of day and night-time intragastric acid secretion.
Hagenmüller
F
F
II. Med. Klinik und Poliklinik der Techn. Universität München, Munich.
D000328:Adult; D002940:Circadian Rhythm; D004311:Double-Blind Method; D005744:Gastric Acid / Q000187:drug effects / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D010418:Pentagastrin / Q000494:pharmacology; D010461:Peptones / Q000494:pharmacology*; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology*; D011897:Random Allocation
D006635:Histamine H2 Antagonists; D010461:Peptones; D010880:Piperidines; C045914:TZU 0460; D010418:Pentagastrin